You need to be logged in to view this video
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Corporate Presentation - Winter '20-'21
Released on Tuesday, January 26, 2021•BIOTECH
Citius Pharmaceuticals will present its progress in the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Citius is advancing three product candidates: 1) Its late-stage lead asset Mino-Lok® is in Phase III trials and is enrolling patients, 2) Halo-Lido (CITI-002) is being prepared for a Phase IIb trial, and 3) Mino-Wrap™ (CITI-101) is in pre-clinical stage. The markets for these products are large, underserved, and provide unique opportunities for the company.
Leonard Mazur
Citius Pharma,
Chairman of the Board
Leonard Mazur, chairman of Citius Pharmaceuticals, Inc., is a highly accomplished pharmaceutical executive with notable accomplishments in founding, building, and creating value and returns for investors. Mr. Mazur is a founder/co-founder of the following companies: Genesis, Triax, Akrimax, and Rouses Point. He previously served as executive vice president at Medicis Pharmaceutical Corporation and VP of sales & marketing at ICN Pharmaceuticals, Inc. and held management positions at BASF/Knoll Pharma and Cooper Labs.
Trending Now
Filter By Category
Filter By Keywords
Loading...